Valuation: Mymetics Corporation

Market Cap 4L 4L 4L 3L 6L 4.23Cr 6L 44.06L 17.14L 2.16Cr 16.47L 16.12L 6.93Cr P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 7.21Cr 6.43Cr 5.99Cr 5.46Cr 10Cr 694.59Cr 10Cr 72Cr 28Cr 354.51Cr 27Cr 26Cr 1.14TCr EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Current year 0
Extreme 0.0003
0
1 year 0
Extreme 0.0003
0
3 years 0
Extreme 0.0003
5.6
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-99.99% 45
+4.16%+3.42%+49.37%+94.17% 7.43TCr
+0.42%-4.01%+19.80%+74.17% 5.7TCr
+0.03%-1.10%+3.66%+34.64% 4.83TCr
-5.11%-3.85%+322.09%+685.18% 4.45TCr
-1.01%-1.84%+28.78%+32.92% 4.38TCr
+0.09%-0.87%+5.09%+108.24% 4.11TCr
-0.54%+2.41%+9.31%+58.85% 3.11TCr
+4.51%+8.22%+37.86%+32.49% 2.9TCr
-1.28%-1.97%-8.11%-13.11% 2.45TCr
Average +0.06%-0.14%+46.79%+100.76% 3.94TCr
Weighted average by Cap. +0.31%-0.46%+55.82%+131.45%

Financials

2021 2022
Net sales 4L 4L 4L 3L 6L 4.14Cr 6L 43.18L 16.8L 2.11Cr 16.14L 15.79L 6.79Cr 10.28L 9L 9L 8L 14.64L 9.9Cr 14.75L 1.03Cr 40.17L 5.05Cr 38.59L 37.76L 16Cr
Net income -47.3L -42.2L -39.31L -35.78L -67.37L -46Cr -67.87L -4.75Cr -1.85Cr -23Cr -1.78Cr -1.74Cr -75Cr -48.05L -42.87L -39.94L -36.34L -68.44L -46Cr -68.95L -4.83Cr -1.88Cr -24Cr -1.8Cr -1.76Cr -76Cr
Net Debt 6.71Cr 5.99Cr 5.58Cr 5.08Cr 9.56Cr 646.22Cr 9.63Cr 67Cr 26Cr 329.82Cr 25Cr 25Cr 1.06TCr 7.17Cr 6.39Cr 5.96Cr 5.42Cr 10Cr 690.37Cr 10Cr 72Cr 28Cr 352.35Cr 27Cr 26Cr 1.13TCr
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
  1. Stock Market
  2. Stocks
  3. MYMX Stock